Page 395 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 8 of 8 Original Research

23. Henegar CE, Westreich DJ, Maskew M, et al. The effect of pregnancy and the 42. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary
postpartum period on adherence to antiretroviral therapy among HIV-infected care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS.
women established on treatment. J Acquir Immune Defic Syndr. 2015;68:477. 2010;24:563–572. https://doi.org/10.1097/QAD.0b013e328333bfb7
https://doi.org/10.1097/QAI.0000000000000501 43. Solomon SS, Mehta SH, McFall AM, et al. Community viral load, antiretroviral
24. Hoffmann CJ, Cohn S, Mashabela F, et al. Treatment failure, drug resistance, and therapy coverage, and HIV incidence in India: A cross-sectional, comparative study.
CD4 T-cell count decline among postpartum women on antiretroviral therapy in Lancet HIV. 2016;3:e183–e190. https://doi.org/10.1016/S2352-3018(16) 00019-9
South Africa. J Acquir Immune Defic Syndr. 2016;71:31–37. 44. Gregson J, Kaleebu P, Marconi VC, et al. Occult HIV-1 drug resistance to thymidine
25. Myer L, Phillips T, McIntyre J, et al. HIV viraemia and mother-to-child transmission analogues following failure of first-line tenofovir combined with a cytosine
risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa. analogue and nevirapine or efavirenz in sub Saharan Africa: A retrospective multi-
HIV Med. 2017;18:80–88. https://doi.org/10.1111/hiv.12397 centre cohort study. Lancet Infect Dis. 2017;17:296–304. https://doi.org/10.1016/
S1473-3099(16)30469-8
26. Myer L, Dunning L, Lesosky M, et al. Frequency of viremic episodes in HIV-infected
women initiating antiretroviral therapy during pregnancy: A cohort study. Clin 45. Gregson J, Tang M, Ndembi N, et al. Global epidemiology of drug resistance after
Infect Dis. 2017;64:422–427. failure of WHO recommended first-line regimens for adult HIV-1 infection: A
27. Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further multicentre retrospective cohort study. Lancet Infect Dis. 2016;16:565–575.
https://doi.org/10.1016/S1473-3099(15)00536-8
decline in mother-to-child HIV transmission rates, 2000–2011. AIDS.
2014;28:1049–1057. https://doi.org/10.1097/QAD.0000000000000212 46. Bulage L, Ssewanyana I, Nankabirwa V, et al. Factors associated with virological
28. Mnyani CN, Simango A, Murphy J, Chersich M, McIntyre JA. Patient factors to non-suppression among HIV-positive patients on antiretroviral therapy in Uganda,
August 2014–July 2015. BMC Infect Dis. 2017;17:326. https://doi.org/10.1186/
target for elimination of mother-to-child transmission of HIV. Global Health. s12879-017-2428-3
2014;10:36. https://doi.org/10.1186/1744-8603-10-36
29. Cragg CD. Evaluating viral load monitoring in antiretroviral-experienced HIV- 47. Dharan NJ, Cooper DA. Long-term durability of HIV viral load suppression. Lancet
HIV. 2017;4(7):e279–e280. https://doi.org/10.1016/S2352-3018(17)30063-2
positive pregnant women accessing antenatal care in Khayelitsha, Cape Town
[doctoral dissertation]. Cape Town, South Africa: University of Cape Town; 2015. 48. Burch LS, Smith CJ, Anderson J, et al. Socioeconomic status and treatment
30. Sagna T, Bisseye C, Compaore TR, et al. Prevention of mother-to-child HIV-1 outcomes for individuals with HIV on antiretroviral treatment in the UK: Cross-
sectional and longitudinal analyses. Lancet Public Health. 2016;1:e26–e36.
transmission in Burkina Faso: Evaluation of vertical transmission by PCR, molecular https://doi.org/10.1016/S2468-2667(16)30002-0
characterization of subtypes and determination of antiretroviral drugs resistance.
Glob Health Action. 2015; 8:26065. https://doi.org/10.3402/gha.v8.26065 49. Azia IN, Mukumbang FC, Van Wyk B. Barriers to adherence to antiretroviral
31. Omole OB, Semenya M-AM. Treatment outcomes in a rural HIV clinic in South treatment in a regional hospital in Vredenburg, Western Cape, South Africa. S Afr
J HIV Med. 2016;17:1–8. https://doi.org/10.4102/sajhivmed.v17i1.476
Africa: Implications for health care. S Afr J HIV Med. 2016;17:1–6. https://doi.
org/10.4102/sajhivmed.v17i1.414 50. Matthews LT, Ribaudo HB, Kaida A, et al. HIV-infected Ugandan women on
antiretroviral therapy maintain HIV-1 RNA suppression across periconception,
32. Calvert C, Ronsmans C. Pregnancy and HIV disease progression: A systematic pregnancy, and postpartum periods. J Acquir Immune Defic Syndr. 2016;71:399–
review and meta-analysis. Trop Med Int Health. 2015;20:122–145. https://doi. 406. https://doi.org/10.1097/QAI.0000000000000874
org/10.1111/tmi.12412
33. Heffron R, Donnell D, Kiarie J, et al. A prospective study of the effect of pregnancy 51. Mekuria LA, Nieuwkerk PT, Yalew AW, Sprangers MAG, Prins JM. High level of
virological suppression among HIV-infected adults receiving combination
on CD4 counts and plasma HIV-1 RNA concentrations of antiretroviral-naive HIV-1 antiretroviral therapy in Addis Ababa, Ethiopia. Antivir Ther. 2016;21:385–396.
infected women. J Acquir Immune Defic Syndr. 2014;65:231. https://doi. https://doi.org/10.3851/IMP3020
org/10.1097/QAI.0000000000000013
34. Myer L, Phillips TK, Hsiao N-Y, et al. Plasma viraemia in HIV-positive pregnant 52. McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression
after 12 months of antiretroviral therapy in low-and middle-income countries: A
women entering antenatal care in South Africa. J Int AIDS Soc. 2015;18:20045. systematic review. Bull World Health Organ. 2013;91:377–85. https://doi.
https://doi.org/10.7448/IAS.18.1.20045 org/10.2471/BLT.12.112946
35. Chesney M, Ickovics J. ACTG Adherence baseline questionnaire. San Francisco, CA: 53. Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication
AIDS Clinical Trial Group, University of California San Francisco; 1997. adherence behavior: Recommendations on optimal use. Trans Behav Med.
36. Muzigaba M, Kolbe-Alexander TL, Wong F. The perceived role and influencers of 2015;5:470–482. https://doi.org/10.1007/s13142-015-0315-2
physical activity among pregnant women from low socioeconomic status 54. Chaiyachati K, Hirschhorn LR, Tanser F, Newell M-L, Bärnighausen T. Validating five
communities in South Africa. J Phys Act Health. 2014;11:1276–1283. https://doi. questions of antiretroviral nonadherence in a public-sector treatment program in
org/10.1123/jpah.2012-0386 rural South Africa. AIDS Patient Care STDs. 2011;25:163–170. https://doi.
37. Solarin I, Black V. ‘They told me to come back’: Women’s antenatal care booking org/10.1089/apc.2010.0257
experience in inner-city Johannesburg. Matern Child Health J. 2013;17:359–367. 55. Mindry DL, Milford C, Greener L, et al. Client and provider knowledge and views
https://doi.org/10.1007/s10995-012-1019-6 on safer conception for people living with HIV (PLHIV). Sex Reprod Healthc.
38. Cloete A, Strebel A, Simbayi L, et al. Challenges faced by people living with HIV/ 2016;10:35–40. https://doi.org/10.1016/j.srhc.2016.03.005
AIDS in Cape Town, South Africa: Issues for group risk reduction interventions. 56. Haffejee F, Ports KA, Mosavel M. Knowledge and attitudes about HIV infection and
AIDS Res Treat [serial online]. 2010 [cited 2018 Jan 26];2010:420270: Available prevention of mother to child transmission of HIV in an urban, low income community
from: https://www.hindawi.com/journals/art/2010/420270/abs/ in Durban, South Africa: Perspectives of residents and health care volunteers. Health
39. Chetty T, Newell ML, Thorne C, Coutsoudis A. Viraemia before, during and after SA Gesondheid. 2016;21:171–178. https://doi.org/10.4102/hsag.v21i0.949
pregnancy in HIV-infected women on antiretroviral therapy in rural KwaZulu- 57. Pillay Y. Implementation of the universal test and treat strategy for HIV positive
Natal-South Africa, 2010–2015. Trop Med Int Health. 2018;23(1):79–91. https:// patients and differentiated care for stable patients. Department of Health, South
doi.org/10.1111/tmi.13001 Africa; 2016. Avaiable from https://sahivsoc.org/Files/22%208%2016%20
40. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to Circular%20UTT%20%20%20Decongestion%20CCMT%20Directorate.pdf
resistance in human immunodeficiency virus (HIV) subtype C during first-line 58. Crankshaw TL, Smit JA, Beksinska ME. Placing contraception at the centre of the
antiretroviral therapy. Clin Infect Dis. 2009;49:1928–1935. https://doi.org/ HIV prevention agenda. Afr J AIDS Res. 2016;15:157–162. https://doi.org/10.2989/
10.1086/648444 16085906.2016.1204330
41. El-Khatib Z, Ekström AM, Ledwaba J, et al. Viremia and drug resistance among 59. South African National Department of Health. National consolidated guidelines
HIV-1 patients on antiretroviral treatment – A cross-sectional study in Soweto, for the prevention of mother-to-child transmission of HIV (PMTCT) and the
South Africa. AIDS. 2010;24:1679. https://doi.org/10.1097/QAD.0b013e32833 management of HIV in children, adolescents and adults. Pretoria: South African
a097b National Department of Health; 2015. Contract No.: 11 December.

http://www.sajhivmed.org.za 388 Open Access